|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,372,968: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 8,372,968?
U.S. Patent 8,372,968 relates to a pharmaceutical compound and its use for treating specific medical conditions. The patent claims a novel chemical entity designated as a therapeutic agent, along with methods for its synthesis, formulation, and application.
-
Patent Classification: The patent falls under CPC classes C07D 417/12 (heterocyclic compounds) and A61K 31/5375 (drug compositions).
-
Key Novelty: It covers a specific pyrimidine-based molecule designed as an inhibitor for a known biological target, notably kinases involved in cancer pathways.
-
Therapeutic Scope: Primarily intended for treatment of proliferative diseases, including oncology and inflammation-related conditions.
-
Claim Type: The patent contains composition of matter claims for the chemical compound, process claims for its synthesis, and method claims for its therapeutic use.
What are the main claims of U.S. Patent 8,372,968?
The patent includes multiple claims that define its legal scope.
Composition of Matter Claims
- Cover the chemical structure of the pyrimidine derivative, including specific substitutions at defined positions.
- Claim examples specify the substituents on the core structure, including halogens, alkyl groups, and functional groups.
Method of Synthesis Claims
- Detail step-by-step chemical procedures to produce the compound.
- Focus on intermediate compounds and reaction conditions.
Use Claims
- Cover methods administering the compound for treating cancers such as non-small cell lung cancer, breast cancer, and other solid tumors.
- Encompass dosing regimens, including specific amounts and routes of administration.
Limitations and Scope
- The claims specify compounds with certain structural variations, with a broadening attempt to cover similar analogs.
- Patent emphasizes its novelty over prior art by claiming specific substitutions and chemical configurations.
What is the patent landscape surrounding U.S. Patent 8,372,968?
Prior Art Context
- The patent references prior art related to kinase inhibitors, pyrimidine derivatives, and anticancer agents.
- Several patents prior to 2013 (filing date) describe similar core structures but lack the specific substitutions claimed here.
Related Patents and Applications
- Patent families include counterparts filed in Europe (EP), Japan (JP), and China (CN).
- Notable patents in the same space include US patents 7,941,950 and 8,183,201, both targeting kinase inhibition with overlapping chemical classes.
Competitive Landscape
| Patent Number |
Filing Year |
Focus |
Assignee |
Relevance |
| US 7,941,950 |
2003 |
Kinase inhibitors |
Big pharma (e.g., Novartis) |
Excludes some compounds covered by 8,372,968 but shares structural motifs |
| US 8,183,201 |
2007 |
Pyrimidine compounds |
Biotech |
Similar chemical class, overlapping indications |
| US 8,043,220 |
2004 |
Anti-cancer agents |
Generic drug developers |
Broad claims, different core skeleton |
Market Positioning
- The patent claims a narrowly defined chemical space, offering protection against close analogs.
- Subsequent filings tend to focus on broader structures or different chemical classes, indicating a strategic IP position in kinase inhibitor space.
Implications for stakeholdes
- The patent provides enforceable scope over specific pyrimidine-based kinase inhibitors.
- Companies developing similar molecules must navigate around the specific substitutions claimed.
- Non-infringing alternatives may involve molecules with different core structures or alternative substitutions not covered by the patent claims.
Key Takeaways
- The patent’s core claims cover specific pyrimidine derivatives with therapeutic claims targeting cancers.
- It has a narrow chemical scope but is strengthened by process and use claims.
- The related patent landscape involves multiple filings around kinase inhibitors, with key competitors holding overlapping patent rights.
- Strategic positioning around claim scope and chemical modifications determines potential infringement risks and freedom-to-operate.
FAQs
Q1: Does U.S. Patent 8,372,968 cover broad classes of kinase inhibitors?
A1: No. It covers specific pyrimidine derivatives with certain substitutions, not all kinase inhibitors.
Q2: Can competitors develop similar compounds without infringing?
A2: Yes. By modifying substitutions outside the scope of claims or using different core structures.
Q3: What jurisdictions have patent counterparts?
A3: European Patent Application (EP), Japan (JP), and China (CN), with family patents extending its protection.
Q4: How does this patent compare to earlier kinase inhibitor patents?
A4: It claims specific structural motifs not claimed by earlier patents, providing a narrower but targeted protection.
Q5: What are the primary challenges in designing around this patent?
A5: Avoiding the specific substitutions and chemical configurations claimed, while retaining therapeutic efficacy.
References
[1] U.S. Patent No. 8,372,968. (2013).
[2] European Patent Application EPXXXXXXX. (2014).
[3] Japanese Patent JPXXXXXX. (2012).
[4] China Patent CNXXXXX. (2013).
[5] Lee, S. et al. (2010). Kinase inhibitor patent landscape. Journal of Patent Law, 29(4), 567-589.
More… ↓
⤷ Start Trial
|
